Knockdown of PEBP4 inhibits human glioma cell growth and invasive potential via ERK1/2 signaling pathway.

Phosphatidylethanolamine (PE)-binding protein 4 (PEBP4) is an antiapoptotic protein that is aberrantly expressed in various malignancies. We previously demonstrated that PEBP4 expression is dramatically induced in human gliomas and positively correlated with tumor grade and patient survival. However, the function of PEBP4 in human glioma development and underlying mechanisms remain largely unknown. By stable lentiviral vector-mediated silencing of PEBP4, we examined the effects of PEBP4 knockdown on the growth, apoptosis, and invasion of U251 and U373 human glioma cell lines using MTT, Transwell, colony formation, and flow cytometric assays. We examined the in vivo role of PEBP4 in tumor growth by inoculation of BALB/c nu/nu male mice with PEBP4-deficient U251 and U373 cells. The expression of cell cycle- and apoptosis-related proteins was analyzed by Western blotting and immunostaining. Knockdown of PEBP4 significantly reduced the proliferation and invasion of human glioma cells while inducing cell apoptosis by altering the expression of cell cycle- and apoptosis-related proteins. Mechanistically, PEBP4 knockdown led to activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway, an effect that could be reversed by U0126, a selective inhibitor of MEK1/2 (upstream of ERK1/2), suggesting involvement of ERK1/2 signaling in the regulation of glioma development and progression by PEBP4. We identified PEBP4 as a novel regulator mediating human glioma cell proliferation, invasion, and apoptosis as well as tumor formation and growth. Therefore, PEBP4 may be a potential therapeutic target in human glioma treatment.

Two different methods for acute angle-closure glaucoma with cataract / 国际眼科杂志(Guoji Yanke Zazhi)

· AIM:To investigate the clinical efficacy of phacoemulsification (Phaco) and intraocular lens (IOL) implantation combined with goniosychialysis in the treatment of acute primary angle-closure glaucoma (APACG) with cataract.· METHODS:In this prospective randomized clinical trial,60 eyes of 60 patients with APACG and coexisting cataract were randomized to the control group (30 patients,30 eyes) or the study group (30 patients,30 eyes) and completed the trial.All the two groups were treated with phacoemulsification and intraocular lens implantation,and the control group (30 patients,30 eyes) was combined with trabeculectomy,while the study group (30 patients,30 eyes) was treated with the goniosychialysis.All patients were followed up for 2mo.The preoperative and postoperative best corrected visual acuity (BCVA),intraocular pressure (IOP),anterior chamber depth (ACD),anterior chamber angle(ACA) and complications were compared.· RESULTS:There were no statistically significant differences between the 2 groups in BCVA,IOP,ACD,ACA before surgery(P＞ 0.05).The postoperative BCVA,lOP,ACD and re-opening anterior chamber angle (ACA) in two groups were all improved,and the differences had statistical significance (P ＜ 0.001).BCVA,ACD,re-opening ACA of research group were significantly better than those of the control group (P＜0.05).The decreased IOP of the study group were more than the control group and the complications of the control group were more than the study group,but there was no statistical difference in the postoperative IOP and complications between two groups (P＞0.05).· CONCLUSION:The phacoemulsification and IOL implantation combined with goniosychialysis can improve the vision of patients,decrease IOP,increase ACD,and re-opening anterior chamber angle (ACA) in patients with APACG combined with cataract.It has a positive clinical effect.